Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1200/OP.20.00394 | DOI Listing |
Bull Cancer
October 2021
Université Mohamed-V suissi, institut nationale d'oncologie, faculté de médecine et de Pharmacie de Rabat, service d'oncologie médicale, Rabat, Maroc.
Introduction: Oral anticancer therapy is becoming increasingly developed; their prescription has become a common practice in oncology. However, there is a variability and diversity in prescription practice. Its magnitude has been very little studied in scientific literature.
View Article and Find Full Text PDFJCO Oncol Pract
August 2020
Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC.
Oncologist
August 2020
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
This letter to the editor remarks on additional considerations for the management of febrile neutropenia during the COVID‐19 pandemic, in response to the letter by Boutayeb et al.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!